The Emerging Role of Probiotics and their Derivatives against Biofilm-Producing MRSA: A Scoping Review.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Methicillin-Resistant Staphylococcus aureus* ; Staphylococcal Infections*/drug therapy ; Staphylococcal Infections*/prevention & control ; Staphylococcal Infections*/microbiology ; Probiotics*/therapeutic use; Humans ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Biofilms ; Microbial Sensitivity Tests

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main bacterial pathogens causing chronic infections, mainly because of its capacity to produce biofilm. Biofilm production is one of the underlying strategies for antibacterial drug resistance. Accordingly, preventing and attenuating biofilm production has become an emerging approach to controlling persistent infections. Therefore, this scoping review is aimed at surveying the published literature describing the usage of probiotics and their derivatives against biofilm-producing MRSA.
Methods: Updated literature searches were conducted across seven electronic databases including Web of Science, PubMed, Scopus, Cochrane Library, ProQuest, Embase, and Google Scholar to identify all original published articles about probiotics against MRSA. In this regard, studies were summarized and analyzed in the present review.
Results: In the reviewed studies, various microorganisms and compounds were used as probiotics as follows: Lactobacillus species (8 studies), Enterococcus species (4 studies), Bacillus species (2 studies), Streptomyces species (2 studies), Saccharomyces cerevisiae (1 study), Corynebacterium accolens (1 study), and Lactococcus lactis derived Nisin (3 studies). Based on our comprehensive search, 21 studies with eligibility criteria were included in the present review including 12 studies on clinical strains, 6 studies on ATCC, 2 studies simultaneously on clinical and standard strains, and finally 1 study on food sample.
Conclusions: Our study showed that there was an increasing trend in the number of publications reporting probiotics against biofilm-producing MRSA. The results of this scoping review could use to guide the undertaking of the subsequent systematic reviews. In summary, probiotics with antimicrobial and antibiofilm properties can use as an embedded agent in food products or as a biopharmaceutical in the prevention and treatment of MRSA infections.
Competing Interests: The authors report no declarations of interest.
(Copyright © 2022 Saba Jalalifar et al.)

Curr Pharm Des. 2015;21(16):2073-88. (PMID: 25760338)
Sci Rep. 2016 Jul 11;6:29707. (PMID: 27405275)
Mol Med. 2022 Jan 29;28(1):10. (PMID: 35093033)
ISRN Microbiol. 2014 Feb 13;2014:129580. (PMID: 24693455)
Microb Biotechnol. 2019 Nov;12(6):1097-1100. (PMID: 31284329)
Probiotics Antimicrob Proteins. 2015 Mar;7(1):52-9. (PMID: 25319566)
Biomed Pharmacother. 2022 Jan;145:112352. (PMID: 34840032)
APMIS Suppl. 2013 May;(136):1-51. (PMID: 23635385)
Int J Oral Sci. 2014 Dec;6(4):189-94. (PMID: 25257882)
Curr Pharm Biotechnol. 2009 Jan;10(1):2-18. (PMID: 19149587)
Molecules. 2020 Aug 03;25(15):. (PMID: 32756432)
J Appl Microbiol. 2003;94(6):981-7. (PMID: 12752805)
Pol J Microbiol. 2010;59(4):233-9. (PMID: 21466040)
Curr Microbiol. 2021 Jan;78(1):125-132. (PMID: 33108492)
NPJ Biofilms Microbiomes. 2018 Aug 6;4:16. (PMID: 30155267)
Infect Drug Resist. 2020 Feb 26;13:659-672. (PMID: 32161474)
Probiotics Antimicrob Proteins. 2019 Dec;11(4):1110-1123. (PMID: 30523603)
Int J Food Microbiol. 2013 May 15;163(2-3):96-100. (PMID: 23558192)
Microb Pathog. 2017 Jun;107:129-135. (PMID: 28323149)
J Microbiol Methods. 2006 Apr;65(1):1-9. (PMID: 16154216)
Probiotics Antimicrob Proteins. 2021 Feb;13(1):125-134. (PMID: 32556931)
Pathog Dis. 2014 Apr;70(3):231-9. (PMID: 24453168)
Nat Commun. 2019 Oct 21;10(1):4792. (PMID: 31636263)
Microb Pathog. 2017 Nov;112:5-14. (PMID: 28942174)
APMIS. 2017 Apr;125(4):272-275. (PMID: 28407426)
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S164-S179. (PMID: 30248200)
Front Microbiol. 2016 May 31;7:817. (PMID: 27303396)
IUBMB Life. 2020 Jul;72(7):1271-1285. (PMID: 32150327)
Sci Rep. 2018 Jan 18;8(1):1021. (PMID: 29348589)
Can J Infect Dis Med Microbiol. 2006 Sep;17(5):291-5. (PMID: 18382642)
Microbiol Spectr. 2015 Apr;3(2):MB-0001-2014. (PMID: 26104692)
Microorganisms. 2019 Sep 29;7(10):. (PMID: 31569575)
Microb Pathog. 2020 Oct;147:104393. (PMID: 32711113)
Int Immunopharmacol. 2022 Feb;103:108471. (PMID: 34952466)
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S368-77. (PMID: 18462092)
Pathogens. 2021 Jul 30;10(8):. (PMID: 34451434)
J Appl Microbiol. 2016 Jun;120(6):1449-65. (PMID: 26678028)
Anaerobe. 2012 Oct;18(5):530-8. (PMID: 22959627)
BMC Microbiol. 2014 Aug 14;14:197. (PMID: 25124936)
Nat Rev Microbiol. 2009 Sep;7(9):629-41. (PMID: 19680247)
Microorganisms. 2020 Jul 15;8(7):. (PMID: 32679908)
J Hosp Infect. 2011 Mar;77(3):242-7. (PMID: 21277649)
3 Biotech. 2020 Mar;10(3):112. (PMID: 32117673)
Microorganisms. 2020 Jun 19;8(6):. (PMID: 32575628)
Nature. 2018 Oct;562(7728):532-537. (PMID: 30305736)
Pathogens. 2021 Feb 14;10(2):. (PMID: 33672855)
Biomed Pharmacother. 2022 Mar;147:112670. (PMID: 35123230)
FEMS Microbiol Lett. 2006 Jun;259(1):89-96. (PMID: 16684107)
Front Microbiol. 2016 Apr 18;7:508. (PMID: 27148197)
Iran J Microbiol. 2019 Jun;11(3):246-254. (PMID: 31523409)
IUBMB Life. 2020 Sep;72(9):1856-1869. (PMID: 32516518)
Nat Rev Microbiol. 2019 Apr;17(4):203-218. (PMID: 30737488)
Curr Protein Pept Sci. 2005 Feb;6(1):61-75. (PMID: 15638769)
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11197-202. (PMID: 17592147)
Science. 1999 May 21;284(5418):1318-22. (PMID: 10334980)
J Bacteriol. 2002 Feb;184(4):1140-54. (PMID: 11807075)
Clin Microbiol Rev. 2002 Apr;15(2):167-93. (PMID: 11932229)
Pathog Dis. 2017 Mar 1;75(2):. (PMID: 28158586)
Front Microbiol. 2018 Feb 27;9:327. (PMID: 29535693)
Clin Pharmacol Ther. 2007 Aug;82(2):204-9. (PMID: 17538551)
Antibiotics (Basel). 2020 Feb 03;9(2):. (PMID: 32028684)

0 (Anti-Bacterial Agents)

Date Created: 20230106 Date Completed: 20230109 Latest Revision: 20230111

20231215

PMC9810406

10.1155/2022/4959487

36605101